Ticker Details
uniQure N.V. Ordinary Shares uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
IPO Date:	March 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.46B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.66 | 2.94%
Avg Daily Range (30 D):	$1.05 | 4.41%
Avg Daily Range (90 D):	$1.16 | 3.94%

Institutional Daily Volume
Avg Daily Volume:	.65M
Avg Daily Volume (30 D):	1.87M
Avg Daily Volume (90 D):	2.55M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	80
Avg Trade Size (Sh.) (90 D):	86

Institutional Trades
Total Institutional Trades:	3,148
Avg Institutional Trade:	$1.69M
Avg Institutional Trade (30 D):	$2.07M
Avg Institutional Trade (90 D):	$2.34M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.06M
Avg Closing Trade (30 D):	$2.79M
Avg Closing Trade (90 D):	$4.45M
Avg Closing Volume:	99.36K

News

Feb 23, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges uniQure N.... Source: Bronstein, Gewirtz & Grossman Llc

Feb 21, 2026 @ 12:04 AM ROSEN, NATIONAL TRIAL LAWYERS, Encourages uniQure ... Source: Rosen Law Firm

Feb 20, 2026 @ 7:47 PM QURE Investors Have Opportunity to Lead uniQure N.... Source: The Schall Law Firm

Feb 20, 2026 @ 7:09 AM QURE Investors Have Opportunity to Lead uniQure N.... Source: Prnewswire

Feb 19, 2026 @ 11:00 PM QURE SHAREHOLDER ALERT: Securities Fraud Lawsuit F... Source: Kirby Mcinerney Llp

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-1.38	$-.69
Diluted EPS		$-1.38	$-.69
Revenue		$3.7M	$5.26M
Gross Profit		$3.3M	$4.61M
Net Income / Loss		$-80.53M	$-37.72M
Operating Income / Loss		$-51.04M	$-43.87M
Cost of Revenue		$.4M	$.66M
Net Cash Flow		$343.28M	$36.61M
PE Ratio